Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

Overview of attention for article published in Frontiers in oncology, January 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 7,440 followers.

New article: Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA https://t.co/NMOGbFtQf8 #MDS #mdssm #hematology https://t.co/SJ

31 Jan 2022

Reply Repost Favourite

31 Jan 2022

Reply Repost Favourite

📣Post-hoc Analysis of #Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory #AML and #MDS Resistant to HMA or Venetoclax Plus HMA 👨‍⚕️🥼👩‍⚕️ @fatihmuckun lab Read here 👉 https://t.co/iRdx2g56Va #Immun

15 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.